Hyderabad: Pharma company Hetero on Friday said it has started exporting its generic semaglutide injection portfolio to more than 75 countries as part of a multi-year plan to expand access to type 2 diabetes and obesity treatment.The Hyderabad-based pharmaceutical company said initial rollouts are underway in Africa, Asia and the Middle East, with additional launches planned in other markets subject to regulatory approval.The injectable therapy will be sold under the brand names Truglix, Rolemodel and Moto G. Semaglutide belongs to the GLP-1 class of drugs, which is used in diabetes care and weight management.Hetero said the export launch is part of its broader strategy to improve access to advanced cardio-metabolic therapies, particularly in emerging markets.The company said the products will be offered in multi-dose disposable pen devices designed to suit innovator formats and will be available in multiple strengths, including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg, allowing flexibility in dosing to treat both diabetes and obesity.Hetero said it is awaiting approval from India’s Central Drugs Standard Control Organization (CDSCO) after completing clinical trials in type 2 diabetes and obesity and plans to launch in India after regulatory approval.Dr Vamsi Krishna Bandi, Managing Director of Hetero, said the company aims to provide high quality, affordable generic semaglutide through a single global product platform supported by its manufacturing and development capabilities.He said Hetero will use its commercial networks in Asia, the Middle East, Africa and Latin America to support supply and access. Hyderabad-headquartered Hetero operates in over 145 countries and employs over 30,000 people.